Researchmoz presents this most up-to-date research on"Research Report on China Measles, Mumps and Rubella (MMR) Vaccine Market, 2013-2017".The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.
To Read The Complete Report With TOC Kindly Visit: http://www.researchmoz.us/research-report-on-china-measles-mumps-and-rubella-mmr-vaccine-market-2013-2017-report.html
Measles, mumps and rubella are major
infectious diseases that threaten the health of children. Measles is a
kind of acute respiratory infectious disease caused by measles virus
with rashes covering the whole body. Mumps is a kind of respiratory
infectious disease caused by mumps virus, which can violate organs
including various gland tissues, nervous system, liver, kidney, heart,
joint, etc. Rubella is a kind of acute respiratory infectious disease
caused by rubella virus with light constitutional symptoms and
lymphadenectasis behind the ears and on the necks, without koplik spots.
In China, the incidence rate of
measles declines constantly in recent years. In 2012, the number of
measles patients was 6,183, decreasing by 37.82% YOY, with eight
patients died of measles. In 2012, the incidence rate of measles was
4.6/100,000,000, which still lagged far behind the target set by WHO
(incidence rate: below 1/100,000,000). In 2012, China's lot released
volume of measles vaccines reached 8.651 million person-servings,
decreasing by 43.5% YOY.
From 2010 to 2012, China's incidence
rate of mumps increased year after year. In 2012, the number of mumps
patients was 479,518, increasing by 5.53% YOY; the incidence rate was
354.1/100,000,000 without any death. In 2012, China's lot released
volume of mumps vaccines was about 6.883 million person-servings,
decreasing by 47% YOY.
In 2012, the number of rubella
patients was 40,156 in China, decreasing by 38.74% YOY; the incidence
rate was 29.7/100,000,000 and one patient died. In 2012, China's lot
released volume of rubella vaccines was about 4.44 million
person-servings, decreasing by 6.4% YOY.
Since domestic MMR vaccines were
listed in China National Immunization Program in 2008, Chinese
government has been providing eligible children with free MMR vaccines.
If parents require imported MMR vaccines, it will at their own expenses.
According to long-term trend, MMR
vaccines will gradually replace univalent vaccines or bivalent vaccines,
becoming the mainstream in the market. During 2010 to 2012, China's lot
released volume of MMR vaccines slightly declined, which mainly
resulted from the fact that imported MMR vaccines were restricted. Along
with the implementation of Pharmacopoeia of China (2010 Version), CFDA
has not approved the MMR vaccine of GSK to be sold in China because it
contains antibiotics.
In 2011, a Chinese law office revealed that the
MMR vaccines manufactured by Merck violated the approval process of
imported vaccines in China because it lacked alerts in the specification
and existed safety risks. During 2011 to 2012, China's legal import
volume of MMR vaccines decreased sharply. As a result, China's total lot
released volume of MMR vaccines also decreased to some extent.
In recent years, because China's
newborn population is 16 million or even more every year, the prospect
of MMR vaccines is promising. Although the import of MMR vaccines is
restricted in China, many parents still choose imported MMR vaccines for
their children out of the safety concern on domestic vaccines. These
imported MMR vaccines are sold in some private clinics, which may come
from smuggling.
Through this report, readers can acquire the following information:
- Government Policies and Events in China MMR Vaccine Market
- Supply Status of MMR Vaccines in China
- Market Demand of MMR Vaccines in China
- Major Enterprises Providing MMR Vaccines in China Market
- Factors Influencing the Development of China MMR Vaccine Market
- Prospect of China MMR Vaccine Market, 2013-2017
The following enterprises and people are proposed to purchase this report:
- Vaccine Manufacturing Enterprises
- Vaccine Trade Enterprises
- Medical Institutions
- Investors and Research Institutes Concerned About Vaccine Industry
Table of Contents
1 Development Environment of China Vaccine Industry
1.1 Economic Environment
1.2 Policy Environment
1.3 Chinese Population and the Structure
1.4 Overview on China Medical Industry
1.5 Overview on China Vaccine Market
2 Overview on China MMR Vaccine Market, 2010-2012
2.1 Epidemic Situation of Measles, Mumps and Rubella in China
2.1.1 Measles
2.1.2 Mumps
2.1.3 Rubella
2.2 MMR Vaccine Overview
2.3 Rules on Vaccination Procedures of China National Immunization Program
3 Overview on China MMR Vaccine Market, 2010-2012
3.1 Status of Lot Release
3.1.1 Measles Vaccine
3.1.2 Mumps Vaccine
3.1.3 Rubella Vaccine
3.1.4 MMR Vaccine
3.2 Market Scale
4 Major Manufacturing Enterprises in China MMR Vaccine Market, 2010-2013
4.1 Shanghai Institute of Biological Products Co., Ltd. (SIBP)
4.1.1 Enterprise Profile
4.1.2 Lot Released Volume of MMR Vaccine
4.1.3 Production Capacity of MMR Vaccine in 2013
4.2 Beijing Tiantan Biological Products Co., Ltd.
4. 2.1 Enterprise Profile
4.2.2 Lot Released Volume of MMR Vaccine, 2010-2012
4.2.3 Production Capacity of MMR Vaccine in 2013
4.3 Other Enterprises
5 Forecast on China MMR Vaccine Market, 2013-2017
5.1 Factors Influencing Development
5.2 Forecast on Supply, 2013-2017
5.3 Forecast on Market Demand, 2013-2017
Contact Us:
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
http://www.researchmoz.us/
www.linkedin.com/company/researchmoz
https://twitter.com/researchmoz
https://www.facebook.com/pages/ResearchMoz/267379433319976
Blog: http://researchmoz.blogspot.com
